ANAB
ANAPTYSBIO, INCPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 3 ▲ AnaptysBio reported strong Q4 and full-year 2025 financial results d…
- Mar 27 AnaptysBio is spinning off its biopharma operations into First Track…
- Apr 24 Contract: Delaware Chancery Court Rules in Favor of Anaptys by Dismi…
- Apr 24 ▲ AnaptysBio announced a favorable court ruling in its ongoing litigat…
- Jun 11 ▼ Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 notice of…
- Jun 15 ▼ CEO Dennis Mulroy filed a Form 144 notice of intent to sell 20,000 s…
- Jun 26 ▼ CEO Dennis Mulroy filed a Form 144 on June 26, 2026, indicating inte…
- Jun 29 ▼ Officer Dennis Mulroy filed a Form 144 to sell 9,476 shares (~$601K)…
- Oct 1 ▼ 1 insider sell $249.4K at $49.87
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider sold $249.4K.
- InstitutionsBULLISH
Q3 2026: 26 added (0 new), 15 trimmed or exited.
- AnalystsBULLISH
14 of 15 rate it Buy or better. Every target is above the price.
- EstimatesRISING
Current-quarter EPS estimate $0.730 → $1.055 over 90 days. 0 up, 1 down in 30 days.
- Short sellersSTEADY
Short interest −6.3% to 5.05M shares. 10.8 days to cover, ≈17.1% of shares.
- TrendRANGE
8% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| MORGAN STANLEY | ADD | $20.3M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | TRIM | $18.7M |
| Squarepoint Ops LLC | TRIM | $5.5M |
| Connor, Clark & Lunn Investment Management Ltd. | TRIM | $4.7M |
| CAPITAL FUND MANAGEMENT S.A. | DOUBLED | $4.3M |
| Russell Investments Group, Ltd. | DOUBLED | $4.3M |
| DEUTSCHE BANK AG\ | ADD | $3.5M |
| FRANKLIN TEMPLETON INC | TRIM | $3.5M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
15 analystsPrice is below the lowest target. Median implies +74%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Sep 30, 2026 | JP Morgan MAINTAIN | Overweight |
| Sep 24, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Sep 23, 2026 | Leerink Partners MAINTAIN | Outperform |
| Aug 25, 2026 | TD Cowen MAINTAIN | Buy |
| Aug 24, 2026 | HC Wainwright & Co. REITERATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
RENTON HOLLINGS Director Oct 1, 2026 | SELL | $249.4K |
RENTON HOLLINGS Director Oct 1, 2026 | EXERCISE | $90.2K |
Orwin John A Director Sep 15, 2026 | EXERCISE | 1,300 sh |
Orwin John A Director Jun 15, 2026 | EXERCISE | 6,030 sh |
RENTON HOLLINGS Director Jun 15, 2026 | EXERCISE | 6,030 sh |
Schmid John P. Director Jun 15, 2026 | EXERCISE | 6,030 sh |
Hughes Owen Director May 11, 2026 | AWARD | 11,250 sh |
Murphy Christopher M. Chief Financial Officer May 11, 2026 | AWARD | 25,765 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | $1.05 | $0.10–$2.01 | -31.7% | $52.6M |
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | $3.24 | $2.49–$3.74 | -25.5% | $136.7M |
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
25 filings · 3 press releases · 2 bullish · 15 bearish · 8 neutral- NEUTRAL SC 13G/ANov 16, 2026
Sirenia Capital Management LP filed an amended Schedule 13G disclosing a passive 3.1% stake (924,640 shares) in AnaptysBio as of September 30, 2026, unchanged from the prior filing. The filing is a routine periodic update with no change in position or intent.
🔒 Fresh report (last 24h), subscribers only
- BEARISH PRESS-RELEASENov 12, 2026
AnaptysBio reported Q1 FY2027 (Sep 2026) collaboration revenue of $30.3M, below the $33.5M…
The revenue and EPS miss is significant, but the stock's reaction will likely be dominated by the binary catalysts ahead: the Quimilza PDUFA on Dec 12, 2026, and the GSK litigation judgment in Q4…
- NEUTRAL INST-CLUSTERNov 6, 2026
Four small asset managers added or doubled their ANAB positions in Q3 2026, with Barclays and…
The cluster is too small to move the stock. Monitor Q4 13F filings for larger funds (BlackRock, State Street) to see if they followed suit. The absence of insider buying reduces conviction further.
- NEUTRAL PRESS-RELEASESep 21, 2026
AnaptysBio reported Q2 2026 EPS of $0.07, a 50.5% miss vs consensus of $0.14, though collaboration…
The EPS miss is largely non-operational due to the First Tracks separation and one-time tax benefit; focus on Jemperli royalty growth trajectory (26% YoY) and upcoming binary catalysts: FDA…
All ANAB filing & press-release reports (28)
- SC 13G/A reportNov 16, 2026
- PRESS-RELEASE reportNov 12, 2026
- INST-CLUSTER reportNov 6, 2026
- PRESS-RELEASE reportSep 21, 2026
- INST-CLUSTER reportAug 12, 2026
- 144 reportJun 26, 2026
- DEFA14A reportJun 29, 2026
- 144 reportJun 29, 2026
- 8-K reportJun 22, 2026
- 144 reportJun 17, 2026
- 144 reportJun 15, 2026
- 144 reportJun 11, 2026
- 144 reportJun 10, 2026
- 144 reportJun 8, 2026
- 144 reportJun 5, 2026
- 144 reportJun 5, 2026
- 144 reportMay 22, 2026
- 144 reportJun 3, 2026
- 144 reportJun 1, 2026
- 8-K reportMay 29, 2026
- 144 reportMay 28, 2026
- 144 reportMay 27, 2026
- 144 reportMay 15, 2026
- PRESS-RELEASE reportMay 4, 2026
- PRESS-RELEASE reportApr 24, 2026
- CLUSTER reportMar 27, 2026
- PRESS-RELEASE reportMar 27, 2026
- PRESS-RELEASE reportMar 3, 2026